insideALS for HCPs is…

a place where healthcare professionals—who are interested in learning more about the rapidly changing science of genetic ALS—can find content co-created with medical experts in the field.

Sponsored by Biogen and offered through Invitae

No-charge genetic testing for patients living with ALS and their families

Biogen-sponsored genetic testing offered through Invitae includes more than 20 ALS-associated genes.

About ALS

The progressive loss of motor neurons in the brain and spinal cord is characteristic of ALS.1 It is a complex disease, which is likely underpinned by different pathogenic mechanisms including multiple genetic factors.2

Read more
Genetic ALS

In recent years, researchers have expanded their understanding of the link between genetics and ALS as they’ve searched for new approaches to advancing the care of patients living with ALS.3

Read more
Developments in genetic ALS research

The race to understand the concept of genetic ALS began before anyone even called it by that name. In 1993, mutations in the SOD1 gene were first established as a genetic link to ALS.4 The pace of discovery has accelerated since then.

Read more
Genetic testing

Genetic testing can be considered in patients with a diagnosis of ALS as it may provide a better understanding of the basis of their condition.3,5 Learn more about the potential benefits and risks of genetic testing.

Read more
Supporting patients living with ALS

Supporting patients living with ALS involves providing guidance and information on the progression, impact, and potential cause(s) of the disease, as well as discussing options, such as genetic testing, counseling and the possibility of clinical trial enrollment.1,3,6,7

Read more

*Healthcare professionals are paid consultants for Biogen

References: 1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. NEJM. 2017; 377: 162-72. 2. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404-423. 3. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counselling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267-274. 4. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807-830. 5. Shepheard SR, Parker MD, Cooper-Knock J, et al; on behalf of Project MINE Consortium; Project MinE. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510-518. 6. Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295-2302. 7. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.

References

1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. NEJM. 2017; 377: 162-72. 2. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404-423. 3. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counselling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267-274. 4. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807-830. 5. Shepheard SR, Parker MD, Cooper-Knock J, et al; on behalf of Project MINE Consortium; Project MinE. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510-518. 6. Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295-2302. 7. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.